HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124

Stock Information for Werewolf Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Werewolf Therapeutics Inc.

Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit
Werewolf Therapeutics to Participate in the BIO International Convention
Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference
Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
Werewolf Therapeutics to Participate in Upcoming Investor Conferences
Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.